Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alglucosidase alfa - Sanofi Genzyme

Drug Profile

Alglucosidase alfa - Sanofi Genzyme

Alternative Names: Alglucosidase alpha; human acid alpha-glucosidase; Lumizyme; Myozyme; Pompase; recombinant human acid alpha-glucosidase; rhGAA

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Alpha-glucosidases; Peptides
  • Mechanism of Action Alpha glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glycogen storage disease type II

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 Apr 2017 Long term efficacy pooled data from a phase III and phase IV trial in Glycogen-storage-disease-type-II presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 01 Aug 2014 US FDA approves sBLA for alglucosidase alfa (Lumizyme®) for patients of any age or phenotype with Glycogen storage disease type II in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top